Cancer Genetics to Present at "A Future Without Cancer Conference" on Friday, March 17
March 13, 2017 09:13 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
Cancer Genetics to Report Fourth Quarter & Year End 2016 Earnings and Business Update on March 23
March 10, 2017 11:41 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., March 10, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
Cancer Genetics India Partners with CSIR-Centre for Cellular and Molecular Biology to Organize the 2nd Annual Next Generation Sequencing Conference in India
February 23, 2017 14:33 ET
|
Cancer Genetics, Inc.
Scientists at CSIR-CCMB conduct groundbreaking multi-disciplinary research in the area of modern biology and aim to promote collaborative research using advanced technologies that enable omics-based...
Cancer Genetics, Inc. to Receive $1.0 Million in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
February 22, 2017 08:12 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) an emerging leader in enabling precision medicine for oncology through the use of molecular markers and...
Cancer Genetics, Inc. Hereditary Breast & Ovarian Cancer Panel Selected by Global Biopharma to Power 1,000+ Patient Clinical Study
February 16, 2017 08:15 ET
|
Cancer Genetics, Inc.
Revenue from the study will begin immediately, and the Company expects it to continue through 2018The hereditary breast and ovarian panel, Focus::HERSite™, will also be offered for select...
Cancer Genetics, Inc. to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
February 13, 2017 07:30 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
Cancer Genetics, Inc. Launches Entry into Comprehensive Hereditary Cancer Testing for Breast & Ovarian Cancers, Addressing a $2.5 Billion Market
January 25, 2017 12:48 ET
|
Cancer Genetics, Inc.
CGI believes that hereditary cancer testing will generate significant additional revenue from both clinical and biopharma customers during 2017 and beyond.Launch of hereditary panel, branded...
Precision Oncology Diagnostics Leader, Cancer Genetics, Inc. & Precision Therapeutics Company, Lantern Pharma, Inc. Announce Strategic Collaboration Focused on Drug Rescue & Repurposing Leveraging Genomics, Biomarkers & Artificial Intelligence Driven Development for Multiple Lead Oncology Compounds
January 17, 2017 09:31 ET
|
Cancer Genetics, Inc.
The collaboration will leverage CGI’s biomarker discovery, clinical trial testing, and companion diagnostic development capabilities along with Lantern’s artificial intelligence and big-data driven...
Cancer Genetics, Inc. Announces Multiple Agreements & Collaborations to Develop Liquid Biopsy Programs with Leading Biopharma Companies
January 09, 2017 09:27 ET
|
Cancer Genetics, Inc.
CGI has signed five agreements and contracts to develop focused, high-performance liquid biopsy tests for a broad range of solid tumorsThe liquid biopsy tests are focused on therapy monitoring &...
Cancer Genetics, Inc. Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions
January 06, 2017 17:34 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) an emerging leader in enabling precision medicine for oncology through the use of molecular markers and...